Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Treatment
Volume 2013, Article ID 273695, 5 pages
http://dx.doi.org/10.1155/2013/273695
Clinical Study

Randomized Controlled Trial of Etodolac versus Combination of Etodolac and Eperisone in Patients of Knee Osteoarthritis

1Department of Pharmacology, Government Medical College and Rajindra Hospital, Patiala, Punjab 147001, India
2Department of Pharmacology, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh 160012, India
3Department of Orthopaedics, Government Medical College and Rajindra Hospital, Patiala, Punjab 147001, India

Received 27 July 2013; Revised 17 August 2013; Accepted 17 August 2013

Academic Editor: Robert L. Barkin

Copyright © 2013 Navjot Kaur et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Chopra, J. Patil, V. Billempelly, J. Relwani, and H. S. Tandle, “Prevalence of rheumatic diseases in a rural population in western India: a WHO-ILAR COPCORD study,” The Journal of the Association of Physicians of India, vol. 49, pp. 240–246, 2001. View at Google Scholar · View at Scopus
  2. J. Lutzner, P. Kasten, K. P. Gunther, and S. Kirschner, “Surgical options for patients with osteoarthritis of the knee,” Nature Reviews Rheumatology, vol. 5, no. 6, pp. 309–316, 2009. View at Publisher · View at Google Scholar
  3. P. Creamer and M. C. Hochberg, “Osteoarthritis,” The Lancet, vol. 350, no. 9076, pp. 503–509, 1997. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Grosser and E. M. Smyth, “Antiinflammatory, antipyretic and analgesic agents,” in Goodman and Gilman’s the Pharmacological Basis of Therapeutics, L. Bruton, B. A. Chabner, and B. C. Knollmann, Eds., p. 985, McGraw-Hill, New York, NY, USA, 12th edition, 2011. View at Google Scholar
  5. K. Inoue, A. Motonaga, J. Dainaka et al., “Effect of etodolac on prostaglandin E2 biosynthesis, active oxygen generation and bradykinin formation,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 51, no. 6, pp. 457–462, 1994. View at Publisher · View at Google Scholar · View at Scopus
  6. P. A. Bacon, “Etodolac: efficacy in osteoarthritis and effects on chondrocyte function,” Rheumatology International, vol. 10, pp. 3–7, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Ryder, I. Salom, G. Jacob, M. Sanda, and J. Huth, “The safety profile of a new structurally novel nonsteroidal anti-inflammatory drug,” Current Therapeutic Research, vol. 33, no. 6, pp. 948–965, 1983. View at Google Scholar · View at Scopus
  8. F. E. Silverstein, G. Faich, J. L. Goldstein et al., “Gastrointestinal toxicity with Celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and reumatoid arthritis: the CLASS study: a randomized controlled trial,” The Journal of the American Medical Association, vol. 284, no. 10, pp. 1247–1255, 2000. View at Google Scholar · View at Scopus
  9. G. A. FitzGerald and C. Patrono, “The coxibs, selective inhibitors of cyclooxygenase-2,” The New England Journal of Medicine, vol. 345, no. 6, pp. 433–442, 2001. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Iwase, T. Mano, M. Saito, and G. Ishida, “Effect of a centrally-acting muscle relaxant, eperisone hydrochloride, on muscle sympathetic nerve activity in humans,” Functional Neurology, vol. 7, no. 6, pp. 459–470, 1992. View at Google Scholar · View at Scopus
  11. K. Bose, “The efficacy and safety of eperisone in patients with cervical spondylosis: results of a randomized, double-blind, placebo-controlled trial,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 21, no. 3, pp. 209–213, 1999. View at Publisher · View at Google Scholar · View at Scopus
  12. K. D. Brandt, “Osteoarthritis,” in Harrison’s Principles of Internal Medicine, D. L. Kasper, A. S. Fauci, D. L. Longo, E. Braunwald, S. L. Hauser, and J. L. Jameson, Eds., p. 2039, McGraw-Hill, New York, NY, USA, 16th edition, 2005. View at Google Scholar
  13. G. Majani, A. Giardini, and A. Scotti, “Subjective impact of osteoarthritis flare-ups on patients' quality of life,” Health and Quality of Life Outcomes, vol. 3, pp. 14–19, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Bolognese, T. J. Schnitzer, and E. W. Ehrich, “Response relationship of VAS and Likert scales in osteoarthritis efficacy measurement,” Osteoarthritis and Cartilage, vol. 11, no. 7, pp. 499–507, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Perpignano, A. Bogliolo, and L. Puccetti, “Double-blind comparison of the efficacy and safety of etodolac SR 600 mg U.I.D. and of tenoxicam 20 mg U.I.D. in elderly patients with osteoarthritis of the hip and of the knee,” International Journal of Clinical Pharmacology Research, vol. 14, no. 5-6, pp. 203–216, 1994. View at Google Scholar · View at Scopus
  16. H. Berry, S. P. Liyanage, R. A. Durance, J. D. Goode, and A. J. Swannell, “A double-blind study of benorylate and chlormezanone in musculoskeletal disease,” Rheumatology and Rehabilitation, vol. 20, no. 1, pp. 46–49, 1981. View at Google Scholar · View at Scopus